Form 10-Q QuidelOrtho Corp For: Sep 27

Wed, 04 Nov 2026 06:00:00 -0500

si-local-file:///var/storage/secattach/20261104/27284857.html

Quidel Corp (QDEL) Tops Q3 EPS by 11c; Offers Guidance

Tue, 03 Nov 2026 16:27:53 -0500

Quidel Corp (NASDAQ: QDEL) reported Q3 EPS of $0.31, $0.11 better than the analyst estimate of $0.20. Revenue for the quarter came in at $618.9 million versus the consensus estimate of $628.08 million.

GUIDANCE:

Quidel Corp sees FY2026 EPS of $0.65-$0.90, versus the consensus of $0.77. Quidel Corp sees FY2026 revenue of $2.52-2.6 billion, versus the consensus of $2.54 billion.

For earnings history and earnings-related data on Quidel Corp (QDEL) click here.

Quidel Corp (QDEL) Tops Q3 EPS by 11c; Offers Guidance

Tue, 03 Nov 2026 16:27:53 -0500

GUIDANCE:

Quidel Corp sees FY2026 EPS of $0.65-$0.90, versus the consensus of $0.77. Quidel Corp sees FY2026 revenue of $2.52-2.6 billion, versus the consensus of $2.54 billion.

For earnings history and earnings-related data on Quidel Corp (QDEL) click here.

Form 8-K QuidelOrtho Corp For: Nov 03

Tue, 03 Nov 2026 16:09:00 -0500

si-local-file:///var/storage/secattach/20261103/27281891.html

QuidelOrtho Reports Third Quarter 2026 Financial Results

Tue, 03 Nov 2026 16:05:00 -0500

― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ―

― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ―

― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ―

QuidelOrtho Reports Third Quarter 2026 Financial Results

Tue, 03 Nov 2026 16:05:00 -0500

― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ―

― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ―

― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ―

Transforming Data Into Actionable Insights in the Lab

Thu, 29 Oct 2026 15:27:00 -0500

SAN DIEGO, Oct. 29, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 62 of its Science Bytes podcast, exploring best practices in AI and informatics to make lab operations smoother.

Transforming Data Into Actionable Insights in the Lab

Thu, 29 Oct 2026 15:27:00 -0500

QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026

Tue, 20 Oct 2026 08:00:00 -0500

SAN DIEGO, Oct. 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, announced today that it will issue a press release to report its financial results for the third quarter 2026 ended September 27, 2026, shortly after the market closes at 4:00 p.m. ET on Tuesday, November 3, 2026.

QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026

Tue, 20 Oct 2026 08:00:00 -0500

Form 4 QuidelOrtho Corp For: Oct 15 Filed by: Siegrist Jonathan Philip

Mon, 19 Oct 2026 17:08:00 -0500

si-local-file:///var/storage/secattach/20261019/27204708.html

QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 15 Oct 2026 18:10:00 -0500

SAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of equity awards to two newly hired, non-executive employees (the "Inducement Grants"). The Inducement Grants were granted pursuant to the Company's 2026 Inducement Plan and as an inducement material to each employee's entering into employment with the Company

QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 15 Oct 2026 18:10:00 -0500

Form SCHEDULE 13G/A QuidelOrtho Corp Filed by: FMR LLC

Wed, 07 Oct 2026 11:47:00 -0500

si-local-file:///var/storage/secattach/20261007/27159974.html

QuidelOrtho names Sanjeev Sharma as VP of investor relations

Wed, 07 Oct 2026 07:13:09 -0500

QuidelOrtho Corporation (NASDAQ: QDEL) has appointed Sanjeev Sharma, CFA, as Vice President of Investor Relations, effective September 28, 2026, according to a company statement.

Sharma brings more than 20 years of experience in investor relations, corporate strategy, and equity research. He most recently served as Senior Director of Investor Relations at Teva Pharmaceuticals, where he worked with senior leadership on investor communications. Before that, he spent more than a decade at Genpact in investor relations and business strategy roles, and nearly six years earlier in sell-side equity research. He holds a master's degree in finance and the CFA designation.

Micah Young, Chief

QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations

Wed, 07 Oct 2026 07:13:00 -0500

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026.

Sanjeev Sharma, Vice
</article>
<article>
<h1>QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations</h1>
<p>Wed, 07 Oct 2026 07:13:00 -0500</p>
<div class=

Sanjeev Sharma, Vice
</article>
<article>
<h1>Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment</h1>
<p>Thu, 24 Sep 2026 09:12:00 -0500</p>
<div class=

SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.
Sepsis remains a leading cause of death in the U.S. Barriers to diagnosis lead to organ failure and higher mortality rates.

Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment

Thu, 24 Sep 2026 09:12:00 -0500

Form 8-K QuidelOrtho Corp For: Sep 23

Wed, 23 Sep 2026 16:41:00 -0500

si-local-file:///var/storage/secattach/20260923/27097150.html

Form 4 QuidelOrtho Corp For: Sep 15 Filed by: Bowman Ronald Lee

Thu, 17 Sep 2026 18:32:00 -0500

si-local-file:///var/storage/secattach/20260917/27077066.html

Faster Answers, Better Decisions: ADLM 2026 Highlights

Thu, 27 Aug 2026 09:12:00 -0500

SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference.

Episode 60: QuidelOrtho
</article>
<article>
<h1>Faster Answers, Better Decisions: ADLM 2026 Highlights</h1>
<p>Thu, 27 Aug 2026 09:12:00 -0500</p>
<div class=

StreetInsider.com News Articles

Form 10-Q QuidelOrtho Corp For: Sep 27

Quidel Corp (QDEL) Tops Q3 EPS by 11c; Offers Guidance

Quidel Corp (QDEL) Tops Q3 EPS by 11c; Offers Guidance

Form 8-K QuidelOrtho Corp For: Nov 03

QuidelOrtho Reports Third Quarter 2026 Financial Results

QuidelOrtho Reports Third Quarter 2026 Financial Results

Transforming Data Into Actionable Insights in the Lab

Transforming Data Into Actionable Insights in the Lab

QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026

QuidelOrtho to Report Third Quarter 2026 Financial Results on November 3, 2026

Form 4 QuidelOrtho Corp For: Oct 15 Filed by: Siegrist Jonathan Philip

QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

QuidelOrtho Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form SCHEDULE 13G/A QuidelOrtho Corp Filed by: FMR LLC

QuidelOrtho names Sanjeev Sharma as VP of investor relations

QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations

Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment

Form 8-K QuidelOrtho Corp For: Sep 23

Form 4 QuidelOrtho Corp For: Sep 15 Filed by: Bowman Ronald Lee

Faster Answers, Better Decisions: ADLM 2026 Highlights